|Source||Humanized (from mouse)|
|Chemical and physical data|
|Molar mass||ca. 150 kg/mol|
|(what is this?)|
Fontolizumab (planned trade name HuZAF) is a humanized monoclonal antibody and an immunosuppressive drug for the treatment of auto-immune diseases like Crohn's disease. A phase II clinical trial investigating the use for rheumatoid arthritis was terminated because the first phase did not meet the endpoint.
- Statement On A Nonproprietary Name Adopted By The Usan Council - Fontolizumab, American Medical Association.
- Reinisch, W; De Villiers, W; Bene, L; Simon, L; Rácz, I; Katz, S; Altorjay, I; Feagan, B; et al. (2009). "Fontolizumab in moderate to severe Crohn's disease: A phase 2, randomized, double-blind, placebo-controlled, multiple-dose study". Inflammatory bowel diseases. 16 (2): 233–42. doi:10.1002/ibd.21038. PMID 19637334.
- Clinical trial number NCT00281294 for "A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis" at ClinicalTrials.gov
|This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.|
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|